Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OptiMalVax

Financiado

Cerrado

Optimizing a deployable high efficacy malaria vaccine

A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and developm... ver más

31/12/2022

UOXF

24M€

Presupuesto del proyecto: 24M€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 22 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

SC1-PM-06-2016: Vaccine development for malaria and...

I+D

Cerrada hace 8 años

0% 84% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

22 Participantes

UOXF

12.06M€ | Lider

UBE CORPORATION EUROPE

348.48K€ | Participante

NOVAVAX AB

150.00K€ | Participante

OSIVAX

19.84K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

OPTIMALVAC Initiative on Optimizing Malaria Vaccine Lab Assays Evaluati... 2M€ Cerrado

MultiMalVax A Multi Stage Malaria Vaccine 8M€ Cerrado

FIGHTMAL Correlating protection against malaria with serum profiles a... 2M€ Cerrado

PREMALSTRUCT Structural analysis of the CSA binding interactions involved... 3M€ Cerrado

OptiViVax Optimising a High Efficacy Plasmodium vivax Malaria Vaccine 4M€ Cerrado

GENETICHTS REVEAL PF Genetic High Throughput Screenings by random mutagenesis to... 100K€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2016-12-09
Fecha Fin: 2022-12-31

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 24M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates. Our approach tackles the toughest problems in malaria vaccine design: choice of the best antigens, attaining high immunogenicity, avoiding polymorphic antigens and increasing the durability of vaccine immunogenicity and efficacy. We take advantage of several recent advances in vaccinology and adopt some very new technologies: sequencing malaria peptides eluted from the HLA molecules, parasites expressing multiple transgenes, multi-antigen virus-like particles constructed with new bonding technologies, delayed release microcapsules, and liver-targeted immunisation with vaccine vectors. We enhance our chances of success by using a multi-stage multi-antigen approach, by optimising the magnitude and durability of well-characterised immune responses to key antigens, and using stringent infectious challenges and functional assays as established criteria for progression at each stage. The consortium comprises many of the foremost researchers in this field in Europe with leading groups in the USA, Australia and Africa. We link to EDCTP programmes and harmonise our timeline to fit with the recent roadmaps for malaria vaccine development. We include a major pharma partner and several excellent European biotech companies helping enhance Europe’s leading position in the commercial development of vaccines. This ambitious and exciting programme should have a high chance of success in tackling the major global health problem posed by malaria.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores